Published Paper Details:

Lenvatinib, a multi-targeted tyrosine kinase inhibitor, has shown promising anticancer activity against various malignancies. However, its clinical application is hindered by poor aqueous solubility, low bioavailability, and off-target toxicity. To address these limitations, liposomal drug delivery systems have emerged as an effective strategy to improve the pharmacokinetic and pharmacodynamic profiles of anticancer agents. In this study, we developed and characterized a novel liposomal formulation encapsulating Lenvatinib, aiming to enhance its therapeutic efficacy while minimizing adverse effects. The liposomes were prepared using a thin-film hydration method and optimized for particle size, encapsulation efficiency, and stability. Physicochemical characterization demonstrated uniform size distribution, high drug loading, and sustained release kinetics. In vitro studies revealed enhanced cellular uptake and cytotoxicity of Lenvatinib-loaded liposomes compared to free drug in various cancer cell lines. Furthermore, in vivo pharmacokinetic and biodistribution studies demonstrated prolonged circulation time and increased accumulation of Lenvatinib in tumor tissues following liposomal administration. Moreover, the liposomal formulation exhibited superior antitumor efficacy and reduced systemic toxicity in xenograft mouse models compared to the free drug. Overall, our findings suggest that the developed Lenvatinib-loaded liposomal formulation holds great promise as a targeted and efficacious anticancer therapy, warranting further preclinical and clinical investigations. This study highlights the potential of Lenvatinib-loaded liposomes as a promising approach for the targeted delivery of Lenvatinib, offering enhanced therapeutic efficacy and improved safety profile in the treatment of solid tumors.